Tumor Targeting: is a cancer treatment that uses drugs.... Targeted therapy works by targeting the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. These genes and proteins are found in cancer cells or in cells related to cancer growth, like blood vessel cells.
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Robotic partial nephrectomy (RPN) has increasingly been applied to the treatment of small renal masses. Because of space limitations and the size of the robot at the patient side, the standa...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Come join us for a live chat with Bernd Bodenmiller. When you enter the meeting room you can raise your hand to be unmuted by our moderator to ask your questions or just introduce yourself a...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
MicroRNAs (miRs) are small non-coding RNAs whose expression is altered in several types of human cancers. Recent evidence supports their inter-cellular transfer through extracellular vesicle...
The extracellular matrix (ECM) is a three-dimensional structure that provides physical support for tissues/organs and biochemical/biomechanical cues for tissue morphogenesis, differentiation...
GeoMx Digital Spatial Profiling Technology! The GeoMx Digital Spatial Profiler (DSP) is a novel platform developed by NanoString. This leading digital technology offers multiplexed measureme...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
The selective pressure placed on the resident microbiota by local changes in the host environment – DNA damage, chronic inflammation, metabolic shifts, barrier damage, reduced immunosu...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
DATE: August 26, 2020 TIME: 8:00 am PDT The host immune "recognition" of cancer forms the basis of modern tumor immmunotherapy, a highly targeted treatment option with the demonstr...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Over the last decade the cancer research field has seen a number of advances aimed at increasing the efficacy of treatments, reducing toxic side effects, and decreasing attrition rates of dr...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
In this webinar, Dr. Yuting Sun discusses her research supporting a Phase 1 clinical trial advancing cancer therapies, targeted at metabolic vulnerabilities. Metabolic rewiring is a hallmark...
Metastasis is the main cause of death in cancer patients and one of the most complex biological processes in human diseases (Hanahan et al., 2011). The development of therapies designed to f...
DATE: July 16, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow devel...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Robotic partial nephrectomy (RPN) has increasingly been applied to the treatment of small renal masses. Because of space limitations and the size of the robot at the patient side, the standa...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Come join us for a live chat with Bernd Bodenmiller. When you enter the meeting room you can raise your hand to be unmuted by our moderator to ask your questions or just introduce yourself a...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
MicroRNAs (miRs) are small non-coding RNAs whose expression is altered in several types of human cancers. Recent evidence supports their inter-cellular transfer through extracellular vesicle...
The extracellular matrix (ECM) is a three-dimensional structure that provides physical support for tissues/organs and biochemical/biomechanical cues for tissue morphogenesis, differentiation...
GeoMx Digital Spatial Profiling Technology! The GeoMx Digital Spatial Profiler (DSP) is a novel platform developed by NanoString. This leading digital technology offers multiplexed measureme...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
The selective pressure placed on the resident microbiota by local changes in the host environment – DNA damage, chronic inflammation, metabolic shifts, barrier damage, reduced immunosu...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
DATE: August 26, 2020 TIME: 8:00 am PDT The host immune "recognition" of cancer forms the basis of modern tumor immmunotherapy, a highly targeted treatment option with the demonstr...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Over the last decade the cancer research field has seen a number of advances aimed at increasing the efficacy of treatments, reducing toxic side effects, and decreasing attrition rates of dr...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
In this webinar, Dr. Yuting Sun discusses her research supporting a Phase 1 clinical trial advancing cancer therapies, targeted at metabolic vulnerabilities. Metabolic rewiring is a hallmark...
Metastasis is the main cause of death in cancer patients and one of the most complex biological processes in human diseases (Hanahan et al., 2011). The development of therapies designed to f...
DATE: July 16, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow devel...
Follow
